Hello
John and Doves,
Is
this a coincidence that medical health care employees are
starting to get vaccinated for Ebola? (With all the
recent news coming out on Disease X? - as 'infectious as
measles and as deadly as Ebola'.)
"Denver
Health's High Risk Infection Team said that are some of the
first to receive the live vaccine as a way to be prepared in
the event of a future outbreak. The team is part of
the Regional Emerging Special Pathogen Treatment Center -
one of 13 centers in the U.S. that can treat infectious
diseases like Ebola."
"Even
though there are NO CURRENT OUTBREAKS in the world, we want
to make sure that people have the chance to be protected in
case we need to take care of a patient that has a disease
with a mortality potentially of 70%".
So I looked up Ervebo (a Merck vaccine):
It is a "replication-competent (this virus can replicate), live
attenuated recombinant vesicular stomatitis virus (rVSV)
vaccine manufactured by Merck. It is not
possible to become infected with EBOV (Ebola) from the
vaccine because the vaccine only contains a gene from the
Ebola virus, not the whole virus. Specifically, it
contains a gene for the EBOV glycoprotein that replaces
the gene for the native VSV glycoprotein. (SEE THE
NOTE ON IMMUNOCOMPROMISED INDIVIDUALS IN THE MERCK REPORT
BELOW) ERVEBO does not provide protection
against other species of Ebolavirus or Marburgvirus.
They took a vesicular stomatitis virus (VSV)
and substituted the VSV envelope glycoprotein for the Zaier
ebolavirus' envelope glycoprotein. ERVEBO "was
initially engineered by scientists from the Public Health
Agency of Canada's Microbiology Laboratory. The
technology was licensed to Lumos Pharma, Inc. and Merck
licensed the vaccine in 2014. The following clinical
development program was sponsored by U.S. HHS,
Administration for Strategic Preparedness and Response and
Biomedical Advanced Research and Development Authority
(BARDA).
U.S.
FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live)
for Use in Children 12 Months of Age and Older - Merck.com
A VSV was used to create a Covid-19, SARS-CoV-2
vaccine where a small part of the spike protein was included
with the virus. So this 'technique' to create a vaccine is
not unusual.
And guess who helped evaluate the safety and
immunogenicity of this vaccine? NIAID - Fauci's group)
In December 2019, ERVEBO was approved by the
FDA for individuals 18 years old and older. In August,
2023, the FDA "has approved an expanded indication for
ERVEBO, which is now indicated for the prevention of disease
caused by Zaire ebolavirus in individuals 12 months of age
and older."
In this notice, Merck reported that "the
duration of protection conferred by ERVEBO is unknown."
Does it last three weeks or 6 months or 5 years?
This vaccine has been out since 2019 and there have
been so few outbreaks of Zaire Ebola. And no more info
on this vaccine.
And "Vaccination with ERVEBO may not
protect all individuals." Do these health
care workers know this??
And it does not protect against
other species of Ebolavirus or Marburgvirus (a
cousin of Ebola)
Also, "In January 2021, Merck confirmed an
agreement with UNICEF to establish the world's first global
Ebola vaccine stockpile with ERVEBO to support future Zaire
ebolavirus outbreak, preparedness and response
efforts. As of March 2023, over 500,000 doses of the
licensed vaccine have been delivered to the stockpile, which
is administered by the International Coordinating Group on
Vaccine Provision.
As for IMMUNOCOMPROMISED INDIVIDUALS:
"The risk of vaccination with ERVEBO, a live virus vaccine,
in immunocompromised individuals should be weighed against
the risk of disease due to Zaire ebolavirus." This
sounds like an immunocompromised person could get Ebola from
the live virus vaccine. ??
For just having ONE gene from the Ebola virus
in the vaccine - there sure are a lot of BAD side
effects:
The clinical trials reported: 55% with
headache, 39% with fever, 33% with muscle pain, 26% with
fatigue, 19% with joint pain, 17% with chills, 15% with
decreased appetite, 13% with abdominal pain, 10% with
nausea, 4% with vomiting, 4% with rash, 3% with abnormal
sweating and 2% with mouth ulceration. In those
18 and older.
For babies - 12 months to 2 years: 83%
with fever, 31% with crying, 27% with decreased appetite,
20% with fatigue, 19% with diarrhea, 17% with vomiting, 10%
with screaming, 5% with chills, 2% with abnormal sweating.
After vaccination, individuals will test
positive of Ebola antibody or antigens.
With the associated risks inherent in vaccines
is it really necessary for health care workers in the US to
take this now with no world outbreaks - and it may not
protect everyone vaccinated, and is specific to only one
Ebola virus.
With so many health care workers vaccinated
with Covid-19 'vaccine" that really wrecks havoc on the
immune system - should these people be considered
"immunocompromised"?
Interesting timing with the increase chatter on
Disease X.
Pray for the peace of Jerusalem!
Maranatha!
Chance
This paper reported on research done on Marburg
virus, Lassa virus and Crimean-Congo hemorrhagic fever virus
using the vesicular stomatitis virus to create
vaccines. It seems with success.
This could be how a vaccine could be hurriedly
produced for other pathogens - like Disease X.
And as I wrote above - if there is concern with
immunocompromised individuals getting such vaccines - and
then developing the disease....well, that's one way to
spread it.